Pramodini Medicare Limited
Closed12–14 Aug 2026
Updated 2026-08-21 (IST)
Business overview
We are a diagnostic service provider in India. We provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India.
Profit & Loss
Rs crore · AnnualLatest year highlighted in green. Sparklines show the trend.
| 2023 | 2024 | 2025 | ||
|---|---|---|---|---|
| Sales | 31 | 35 | 38 | |
| Operating Profit | 15 | 16 | 21 | |
| OPM % | 48.0% | 44.1% | 54.8% | |
| Net Profit | 4 | 6 | 10 | |
| Total Debt | 21 | 12 | 11 |
Promoters
- Dr. Chalasani Kuldeep Kumar — Chairman and Managing Director
- Dr. Chalasani Kavitha — Non-Executive Director
- Ms. Chalasani Durga Aashritha — Non-Executive Director
- M/s. Sri Ram Medicare Private Limited — Corporate Promoter
Strengths & risks
Company-stated strengths and disclosed risk factors from the offer document.
- Establishing a Strategic presence across various states of India (p.141)
- Strengthening Our Network with Diversified Models (p.141)
- Technical Capability with robust IT Infrastructure (p.142)
- Dedicated Management Team with Significant Industry Experience (p.142)
- Track record of revenue and financial performance (p.143)
- A significant portion of our revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. (p.27)
- Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects. (p.28)
- We derive substantial portion of our revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on our business. (p.29)
- We are majorly dependent on certain key customers cum patients for a substantial portion of our revenues. (p.30)
- Failure to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability. (p.31)
Peer comparison — DRHP median P/E 14.5x
Live BSE prices| Company | CMP | P/E | OPM% | ROE% | Source |
|---|---|---|---|---|---|
| Invicta Diagnostic Limited | — | 14.5x | — | — | DRHP |
| Krsnaa Diagnostics Limited | Rs 576.1 +4.5% | 19.2x | 30.4% | 11.7% | live |
| Star Imaging & Path Labs Limited | — | 6.6x | — | — | DRHP |
P/E from offer document where live data unavailable. Not a fair-value judgement.
Market & competition
Our diagnostic industry is highly competitive and we face competition from organized as well as unorganized providers. In addition, we compete with many smaller, independent clinical and anatomical laboratories as well as laboratories owned by hospitals and physicians.
Future outlook
Our growth strategy includes expanding into new locations and strengthening our presence in existing markets. We are actively exploring opportunities to expand our network across India, including establishing a diagnostic centre in Bangalore, Karnataka under a Private Private Partnership model.
Never miss an IPO like this
Every upcoming IPO analysed — subscription, GMP and a DRHP breakdown — in your inbox, free. One email when each one opens.
Sources & method
Subscription and issue data come from the NSE and BSE exchange feeds, with the third-party aggregator, clearly labelled, where an exchange feed is unreachable. DRHP analysis is extracted from the offer document itself, every figure cited to its page. Each figure on the page carries its source and its timestamp.
Grey-market premium (GMP) is unregulated.
Every GMP figure is a self-reported grey-market estimate — no exchange, regulator or clearing body records or audits it, and there is no settlement guarantee or recourse. Shown for context only; never decide on GMP alone. New to GMP? The 30-second explainer →